Phase 1a study objectives were met
TSX Exchange Symbol: RVX
CALGARY, April 22 /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today that it has completed dosing of its Phase 1a safety, tolerability and pharmacokinetics study for its lead drug candidate, RVX-208, which addresses the dyslipidemia market. "Initial results from the emerging data are very good," declared Donald J. McCaffrey, President & CEO of Resverlogix. "As reported earlier this year the most remarkable results from this study continue to be the outstanding pharmacokinetics (drugability) of RVX-208. With these successful results in hand we are now planning for our Phase 1b/2a trial which, pending discussions and approval from the FDA, we expect to start later this year."
The primary objectives of the Phase 1a trial were to examine the safety, tolerability and pharmacokinetics of RVX-208. This study successfully met those objectives. In addition to the completed Phase 1a human clinical trial, RVX-208 has been the subject of 126 preclinical studies to date, comprising safety, toxicity, pharmacokinetics and pharmacology studies. The Company has selected the dosages to be used in the 28-day Phase 1b/2a study.
"We are very pleased with these promising results which indicate that RVX-208 is a safe and well tolerated drug," stated Dr. Jan Johansson, MD, PhD, Senior Vice President Medical Affairs of Resverlogix. "We are in the process of finalizing the tables, figures and legends for this past study." A review of the pharmacokinetic data was recently presented at the Arteriosclerosis, Thrombosis and Vascular Biology conference in Atlanta, GA.
About Cardiovascular Disease (CVD)
CVD can be generally defined as any abnormal condition characterized by
dysfunction of the heart and blood vessels. CVD includes atherosclerosis
(especially coronary heart disease which can lead to heart
|SOURCE Resverlogix Corp.|
Copyright©2008 PR Newswire.
All rights reserved